Baseline disease characteristics for patients who experienced disease flare and those who did not during the first 28 weeks (total and in the two treatment arms)
| AM Arm | M Arm | All patients | ||||
|---|---|---|---|---|---|---|
| Flare (n=8) | No flare (n=8) | Flare (n=12) | No flare (n=3) | Flare (n=20) | No flare (n=11) | |
| Age (years, median (IQR)) | 51.5 (35–60.5) | 59.5 (53–62.8) | 63.5 (59.5–66) | 65 (33–65) | 61.5 (53.8–65.5) | 61 (52–65) |
| Disease duration (years, median (IQR)) | 11.2 (7.0–22.3) | 4.8 (3.0–8.2) | 10.9 (5.2–21.9) | 5.5 (4.8–14.6) | 10.9 (5.7–21.9) | 5.2 (3.7–8.2) |
| Time from RA diagnosis to ADA (years, median (IQR)) | 8.5 (3.4–20.7) | 2.5 (0.5–3.3) | 7.6 (4.1–16.2) | 4.8 (3.8–10.3) | 8.5 (4.1–16.3) | 3 (1–4.8) |
| Time on ADA treatment (years, median (IQR)) | 2.0 (1.2–4.1) | 2.4 (0.7–4.7) | 3.8 (1.5–4.3) | 1.0 (0.7–1.0) | 3.0 (1.4–4.2) | 2.3 (0.7–4.3) |
| DAS28 | 2.4 (2.1–2.5) | 1.8 (1.3–2.3) | 1.7 (1.5–2.5) | 1.7 (0.5–1.8) | 2.3 (1.7–2.5) | 1.7 (1.3–1.9) |
| SJC | 0 (0–1.75) | 0 (0–0) | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0 (0–0) |
| TJC | 0.5 (0–2) | 0.5 (0–1.8) | 0 (0–1) | 0 (0–0) | 0 (0–1.8) | 0 (0–1) |
| ESR (mm Hg) | 9 (5.8–15.5) | 6 (4.5–10.5) | 8 (5–10) | 10 (2–10) | 8 (5–11) | 6 (4–10) |
| CRP (mg/L) | 3 (1.1–5.0) | 4.5 (0.6–7.0) | 4.5 (2.5–6.6) | 2.9 (1.4–5) | 4 (1.6–5.2) | 2.9 (1–7) |
| GH | 10 (8–20.5) | 6 (1.5–7.8) | 5.5 (0.5–10) | 5 (1–13) | 8 (4.3–15.3) | 6 (1–8) |
| HAQ | 0.3 (0–0.9) | 0.13 (0–0.7) | 0.4 (0.1–0.7) | 0.4 (0.3–0.5) | 0.4 (0–0.7) | 0.3 (0–0.5) |
| MTX dose (mg) | 20 (15–20) | 20 (15–20) | 18.75 (10.6–20) | 20 (10–20) | 20 (13.1–20) | 20 (15–20) |
Values in bold differ significantly between the flare and no flare groups (p<0.05).
ADA, adalimumab; CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joints; ESR, erythrocyte sedimentation rate; GH, global health assessment (patient visual analogue scale); HAQ, Health Assessment Questionnaire; MTX, methotrexate; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count.